Premium
Early experience with high‐intensity focused ultrasound for the treatment of benign prostatic hypertrophy
Author(s) -
Sullivan L.D.,
McLoughlin M.G.,
Goldenberg L.G.,
Gleave M.E.,
Marich K.W.
Publication year - 1997
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1997.03235.x
Subject(s) - prostatism , medicine , high intensity focused ultrasound , urology , quality of life (healthcare) , muscle hypertrophy , ultrasound , urinary flow , intensity (physics) , prostate , surgery , radiology , cancer , prostate disease , nursing , physics , quantum mechanics
Objective To evaluate the safety and effectiveness of high‐intensity focused ultrasound (HIFU) in patients with benign prostatic hypertrophy (BPH). Patients and methods The study comprised 25 patients (mean age 67 years, range 47–84) with BPH treated using the Sonoblate HIFU device. Patients were evaluated before and after one treatment of HIFU using the American Urological Association (AUA) symptom score, peak urinary flow rate (Qmax) and a quality‐of‐life (QOL) score, and any complications were noted. Results Five patients with large glands were withdrawn because the failure rate was high in these patients. The remaining 20 patients showed a mean improvements in the AUA symptom score (20.25 to 9.56), Qmax (9.2 to 13.7 mL/s) and QOL score (4.75 to 2.50). There were no major complications. Conclusions HIFU is safe, produces minimal side‐effects or complications and relieves the symptoms of prostatism.